Table of contents
I. The 2019 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention, October 18, 2019, at the annual meeting of the Society for Neuroscience [SfN].
II. NIH Funding and You: Early Career and Early Career Investigator Symposium at SFN.
III. NIDA Funding Opportunity Announcements
IV. Call for Abstract Submissions for NIDA Genetics and Epigenetics Meeting, January 13-14, 2020 at NIDA HQ due October 18, 2019
--
The annual NIDA-NIAAA Mini-Convention provides a forum for presentations and discussions of current topics in neuroscience and addiction research. Additionally, the Mini-Convention showcases research by premier early stage and junior investigators and is highlighted by a keynote address from the Jacob P. Waletzky Memorial Award Recipient. This year’s scientific sessions are: 1) Sensing New Opportunities for Addiction Neuroscience; 2) Novel Technologies and Innovative Approaches for Translational Research Targeting Alcohol and Substance Use Disorders; and 3) Rewriting Genes by CRISPR for Substance Dependence and Psychiatric Disorder Research. For additional information, please contact Roger Sorensen, NIDA [ rsorense@mail.nih.gov ] or John Matochik, NIAAA [ jmatochi@mail.nih.gov ], or visit https://apps1.seiservices.com/nida-niaaa/frontiers2019/.
II. NIH Funding and You: Early Career and Early Career Investigator Symposium at SFN.
Date and Time: October 21, 2019 at 6:30-9:00 pm
Location: McCormick Place Convention Center, Room S104
Food: Please visit before attending: Marriott Marquis Chicago, Hyatt Regency McCormick Place, or Hiltons at McCormick Place
There will be presentations from Program and Review staff from the National Institute on Drug Abuse (NIDA, NIH) on fellowships (F30, F31, F32, F99/K00), institutional appointments (T32, R25, K12), transition awards (K99/R00), mentored career development awards (K01, K08, K23, K25), special opportunities for international students, postdoctoral opportunities in NIH laboratories, independent research grants (R01, DP2, R03, and R21), and insights from review. Presentations will be followed by the opportunity to meet with Dr. Apkar Vania Apkarian, T32 directors, and NIDA staff.
A special headliner this year will be Dr. Apkarian, Project Director of the Center for Chronic Pain and Drug Abuse (P50) who will speak on pain, addiction, and P50 workforce opportunities. In keeping with the need to educate attendees about institutional appointments, T32 Project Directors will meet with students during our discussion period.
III. NIDA Funding Opportunity Announcements
RFA-DA-20-010 The Rat Opioid Genome Project: Clinical Trials not Allowed (U01- Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-010.html
Application due date: November 19, 2019, by 5:00 PM local time of applicant organization
RFA-DA-20-027 Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed)
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-027.html
Application due date: January 15, 2020, by 5:00 PM local time of applicant organization
PAR-19-278 Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
https://grants.nih.gov/grants/guide/pa-files/PAR-19-278.html
Next Application due dates: December 18, 2019, and June 24, 2020 by 5:00 PM local time of applicant organization
PAR-18-742 Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)
https://grants.nih.gov/grants/guide/pa-files/par-18-742.html
Next Application due date: November 13, 2019 and February 11, 2020, by 5:00 PM local time of applicant organization
PAR-17-242 Extracellular Vesicles and Substance Use Disorders (R21)
https://grants.nih.gov/grants/guide/pa-files/par-17-242.html
Next Application due dates: November 3, 2019 and March 3, 2020 by 5:00 PM local time of applicant organization
PAR-17-250 Extracellular Vesicles and Substance Use Disorders (R01)
https://grants.nih.gov/grants/guide/pa-files/PAR-17-250.html
Application due dates: November 3, 2019 and March 3, 2020, by 5:00 PM local time of applicant organization
--
IV. Call for Abstract Submissions for NIDA Genetics and Epigenetics Meeting, January 13-14, 2020 at NIDA HQ
The Genetics and Epigenetics Cross Cutting Research Team of the National Institute on Drug Abuse invites you to submit an abstract for the January 13-14, 2020 NIDA Genetics Consortium Meeting at NIDA headquarters, 6001 Executive Blvd, Rockville, MD 20850. Abstract submission opens September 9, 2019 and closes October 18, 2019. We will open registration in early October. Agenda to be posted soon.
Please submit your abstract to NGCAbstracts@nida.nih.gov as a PDF with the following format. PDFs not conforming to this format will be returned.
Submitter Name:
Submitted email:
PI Name (if different):
PI email (if different):
Clever title for your abstract
First Name Last Name1, First Name Last Name1,2, First Name Last Name3, and First Name Last Name1,4
1Department, University; 2Department, University; 3Department, University; 4Department, University
The Abstract should discuss the background, rationale/significance, hypothesis, results and discussion. The font size should be Arial 11 pt. The body of the abstract should be 250 words, maximum and fully justified. Please submit the abstract as a PDF document. Abstracts are due by Midnight PST on October 18, 2019. Abstracts not conforming to this format or sent to another email will not be accepted for review and may be returned to the sender. Abstracts sent to another email will not be returned.
See examples at: (NIDA Genetics Consortium Meeting Abstracts).
The goals of the meeting are to:
- Showcase the exciting research on the genetics and epigenetics of substance use disorders
- Encourage collaboration among investigators with different expertise in genetics and epigenetics
- Foster collaboration between investigators working on the genetics and epigenetics of substance abuse disorders and HIV/AIDS investigators
- Identify new research opportunities in the genetics and epigenetics of substance use disorders
- Provide attendees with an opportunity to meet with NIDA program directors to discuss their ideas for grant applications and funding opportunities
The NIDA Genetics and Epigenetics Cross-Cutting Research Team will select up to 12 abstracts for short talks and up to 160 abstracts for poster presentations. We may invite some investigators to serve as panel discussants. Abstracts should focus on the genetics and epigenetics of substance use disorders in humans or in model systems. We encourage submissions across all career stages (e.g. graduate students, postdoctoral scientists, junior and senior faculty). Abstracts are due by Midnight PST on Oct 18, 2019. Decisions on acceptance of poster presentations and short talks will be made on a rolling basis, and no later than November 15, 2019.
There is no registration fee to attend this meeting, however attendees are responsible for their own travel, meals, and lodging.
Jonathan D. Pollock, Ph.D.
Chief
Genetics, Epigenetics, and Developmental Neuroscience Branch
Division of Neuroscience and Behavior
National Institute on Drug Abuse, NIH
6001 Executive Blvd, Rm. 4267
Bethesda, MD 20892
Tel. 301-435-1309
Email. jpollock@mail.nih.gov
Skype: Dogmacentral1
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment